Global assembling of Academicians, Researchers, Scholars & Industry to disseminate and exchange information at 100+ Allied Academics Conferences
Dr. Harbans Singh has completed his M.D (Kayachikitsa) at the age of 30 years from Himachal Pradesh University, Shimla (India) and completed his PhD (Kayachikitsa) from Rajasthan Ayurveda University, Jodhpur (India) in 2008. He had worked as Associate Professor, Department of Medicine at Desh Bhagat University, Mandi Gobindgarh, Punjab (India). He is presently working as Research Officer (Ay.), Scientist-2 in Central Council of Research in Ayurvedic Science, New Delhi, Ministry of AYUSH, Government of India. He has more than 20 publications of National and International repute. He is engaged in various clinical research projects in the field of respiratory medicine and hepatology. He is also a member several national and international medical and research organizations.
Background: Hepatitis infection has become a major worldwide health problem because the potential nature of course of the disease to cirrhosis and the hepatocellular carcinoma (HCC). Acute viral infection is the most common cause of all forms of hepatitis. The viral hepatitis have been thought to be self limiting in nature but sometimes majority of patients of viral hepatitis have been observed ending up with a serious complications like hepatic failure, etc. So, the clinical study was planned to evaluate the hepatoprotective effect of Bhyumyamalki (Phyllanthus amarus) and Phaltrikadi decoction (an Ayurvedic herbal composition) on scientific parameters.
Aim and objectives: To clinically evaluate the hepatoprotective effect of Bhyumyamalki (Phyllanthus amarus) and Phaltrikadi decoction in patients of acute viral hepatitis. Materials and Methods: This prospective, clinical trial was conducted at Department of Medicine, Desh Bhagat Ayurvedic College & Hospital, Mandi Gobindgarh, Punjab. Only those patients were selected for clinical trial, who presented themselves with anorexia, nausea, vomiting, low grade fever, weakness, dark urine, jaundice and tender hepatomegaly with abnormal liver function test (LFTs). Each patient was subjected to series of laboratory tests such asserum bilirubin, AST, ALT, serum alkaline phosphatase, HbSAg, HCV and liver ultrasound before treatment, after 15 days of treatment and after one month of treatment to know the extent of liver damage as well as the rate of response to trial drugs. In the clinical trial, three groups of patients of viral hepatitis have been studied to evaluate the hepatoprotective effect of Bhumyamalki and Phaltrikadi decoction. The first group was given 50 ml of freshly prepared Bhumyamalki decoction, made from 10 gm of crude drug, twice daily. The second group was given a standardized decoction of herbal composition Phaltrikadi decoction, in a dosage of 50 ml made from 10 gm of crude drug, twice daily. The third group was given 100 gm of glucose powder daily.
Observations and Results: The trial was conducted for one month and liver functions test were periodically evaluated to assess the hepatoprotective effect of drugs under trial. At the end of the trial, group first and second exhibited hepatoprotective efficiency over the control.
Conclusion: Thus it can be concluded that Bhumyamalki and Phaltrikadi decoction drugs are effective in the management of acute viral hepatitis.